MD Simulation Studies for Selective Phytochemicals as Potential Inhibitors against Major Biological Targets of Diabetic Nephropathy
Authors:
- Mohd Adnan KausarMohd Adnan Kausar
- Sadaf AnwarSASadaf Anwar
- Wafa Ali EltaybWEWafa Ali Eltayb
- Mohammed KuddusMKMohammed Kuddus
- Fahmida KhatoonFKFahmida Khatoon
- Amr Ahmed El-ArabeyAmr Ahmed El-Arabey
- Amany Mohammed KhalifaAKAmany Mohammed Khalifa
- Moattar Raza RizviMRMoattar Raza Rizvi
- Mohammad Zeeshan NajmMNMohammad Zeeshan Najm
- Lovnish ThakurLTLovnish Thakur
- Subhabrata KarSKSubhabrata Kar
- Mohnad AbdallaMohnad Abdalla
Open Access
Abstract
Diabetes is emerging as an epidemic and is becoming a public health concern worldwide. Diabetic nephropathy is one of the serious complications of diabetes, and about 40% of individuals with diabetes develop diabetic nephropathy. The consistent feature of diabetes and its associated nephropathy is hyperglycemia, and in some cases, hyperamylinemia. Currently, the treatment includes the use of medication for blood pressure control, sugar control, and cholesterol control, and in the later stage requires dialysis and kidney transplantation, making the management of this complication very difficult. Bioactive compounds, herbal medicines, and extracts are extensively used in the treatment and prevention of several diseases, and some are reported to be efficacious in diabetes too. Therefore, in this study, we tried to identify the therapeutic potential of phytochemicals used in in silico docking and molecular dynamic simulation studies using a library of 5284 phytochemicals against the two potential targets of type 2 diabetes-associated nephropathy. We identified two phytochemicals (i.e., gentisic acid and michelalbine) that target human amylin peptide and dipeptidyl peptidase-4, respectively, with good binding affinity. These phytochemicals can be further evaluated using in vitro and in vivo studies for their anti-hyperglycemia and anti-hyperamylinemia effects.Keywords
Funding Information
- University of Hail (RG-20 154)
This publication has 48 references indexed in Scilit:
- New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern TherapeuticsEvidence-Based Complementary and Alternative Medicine, 2013
- Pathophysiology of the Diabetic Kidney2011
- Up-Regulated Pancreatic Tissue MicroRNA-375 Associates With Human Type 2 Diabetes Through β-Cell Deficit and Islet Amyloid DepositionPancreas, 2010
- Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy SettingPhysical Therapy, 2008
- Epidemiology of Diabetes and Diabetes-Related ComplicationsPhysical Therapy, 2008
- Benchmarking the Reliability of QikProp. Correlation between Experimental and Predicted ValuesQSAR & Combinatorial Science, 2008
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profilingBritish Journal of Pharmacology, 2007
- Amylin deposition in the kidney of patients with diabetic nephropathyKidney International, 2007
- Amyloidosis-Associated Kidney DiseaseJournal of the American Society of Nephrology, 2006
- Lead- and drug-like compounds: the rule-of-five revolutionDrug Discovery Today: Technologies, 2004